- Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
- Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
- Arcellx Provides First Quarter 2024 Financial Results
- Arcellx to Participate in Two Upcoming Investor Conferences
- Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
- Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
More ▼
Key statistics
On Tuesday, Arcellx Inc (ACLX:NSQ) closed at 53.27, -29.07% below its 52-week high of 75.10, set on Mar 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 54.21 |
---|---|
High | 55.45 |
Low | 53.01 |
Bid | 50.46 |
Offer | 56.22 |
Previous close | 54.36 |
Average volume | 527.91k |
---|---|
Shares outstanding | 53.50m |
Free float | 42.71m |
P/E (TTM) | -- |
Market cap | 2.91bn USD |
EPS (TTM) | -1.04 USD |
Data delayed at least 15 minutes, as of May 21 2024 21:00 BST.
More ▼